News

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches.

10/22/2024

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1.

08/15/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is ABVC BioPharma, Inc. (ABVC) a buy, sell, or hold?

ABVC BioPharma, Inc. (ABVC) can sell. Click on Rating Page for detail.

What is ABVC BioPharma, Inc.'s stock price?

The price of ABVC BioPharma, Inc. (ABVC) is 0.5674 and it was updated on 2024-11-21 02:41:04.

Is ABVC BioPharma, Inc. (ABVC) overvalued or undervalued?

Currently ABVC BioPharma, Inc. (ABVC) is in undervalued.

News

From:

To:

News
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life. Thu, Apr. 18, 2024
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. We are hopeful that this agreement will facilitate the advancement of treatments for Non-Small Cell Lung Cancer (NSCLC) since it covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer. ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1,250,000 in cash after OncoX's next round of fundraising, of which there can be no guarantee; ABVC and its affiliate are also entitled to royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product. Wed, Apr. 17, 2024
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products. Wed, Apr. 10, 2024
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. Tue, Mar. 26, 2024
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine . This recognition is a testament to Dr. Patil's outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary. Within his first year as the Company's CEO, the Company saw a rise in the stock price of its common stock, an increase in its social media presence, and a renewed focus on its essential products. Tue, Mar. 19, 2024

SEC Filings

SEC Filings
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 11/15/2024
ABVC BioPharma, Inc. (ABVC) - SC 13G/A SEC Filings 11/14/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/14/2024
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/14/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/04/2024
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 10/25/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/18/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/10/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/20/2024
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 08/16/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/15/2024
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/14/2024
ABVC BioPharma, Inc. (ABVC) - 424B5 SEC Filings 08/07/2024
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 08/02/2024
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 07/26/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/23/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/12/2024
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 07/12/2024
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 07/02/2024
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 06/25/2024
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 06/24/2024
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 06/21/2024
ABVC BioPharma, Inc. (ABVC) - D SEC Filings 05/28/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/24/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/23/2024
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 05/23/2024
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 05/22/2024
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 05/17/2024
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/17/2024
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 05/15/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/15/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/09/2024
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 05/01/2024
ABVC BioPharma, Inc. (ABVC) - PRE 14A SEC Filings 04/26/2024
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 04/25/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/19/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/17/2024
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 04/05/2024
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 04/02/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/26/2024
ABVC BioPharma, Inc. (ABVC) - DEFA14A SEC Filings 03/25/2024
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 03/22/2024
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 03/15/2024
ABVC BioPharma, Inc. (ABVC) - DEFA14A SEC Filings 03/14/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/14/2024
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 03/13/2024
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 02/29/2024
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 02/16/2024
ABVC BioPharma, Inc. (ABVC) - SC 13G/A SEC Filings 02/13/2024
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 02/09/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/08/2024
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 01/26/2024
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 01/17/2024
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/17/2024
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 01/12/2024
ABVC BioPharma, Inc. (ABVC) - DEF 14A SEC Filings 12/29/2023
ABVC BioPharma, Inc. (ABVC) - PRE 14A SEC Filings 12/15/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/20/2023
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 11/17/2023
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 11/17/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/16/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/15/2023
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/15/2023
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 11/14/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/13/2023
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 09/06/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/31/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/17/2023
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 08/17/2023
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 08/17/2023
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/14/2023
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 08/09/2023
ABVC BioPharma, Inc. (ABVC) - SC 13G SEC Filings 08/07/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/07/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/02/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/31/2023
ABVC BioPharma, Inc. (ABVC) - 424B5 SEC Filings 07/31/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/27/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/24/2023
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 07/14/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/07/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/23/2023
ABVC BioPharma, Inc. (ABVC) - DEF 14A SEC Filings 06/21/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/15/2023
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 06/12/2023
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 06/09/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/09/2023
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 06/08/2023
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 06/07/2023
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 06/01/2023
ABVC BioPharma, Inc. (ABVC) - PRE 14A SEC Filings 05/31/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/26/2023
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 05/22/2023
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 05/22/2023
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/15/2023
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 05/10/2023
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 05/02/2023
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 05/02/2023
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 04/26/2023
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 04/24/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/24/2023
ABVC BioPharma, Inc. (ABVC) - DEF 14A SEC Filings 04/14/2023
ABVC BioPharma, Inc. (ABVC) - PRE 14A SEC Filings 04/04/2023
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 04/03/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/31/2023
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 03/31/2023
ABVC BioPharma, Inc. (ABVC) - D SEC Filings 03/02/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/24/2023
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/16/2023
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 11/15/2022
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 11/15/2022
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/14/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/21/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/13/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/09/2022
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 08/25/2022
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 08/25/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/22/2022
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/15/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/14/2022
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 07/12/2022
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 07/12/2022
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 07/11/2022
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 07/11/2022
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 06/24/2022
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 06/24/2022
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 06/23/2022
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 06/22/2022
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 06/21/2022
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 06/21/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/21/2022
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 06/14/2022
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 06/09/2022
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 06/06/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/01/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/25/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/17/2022
ABVC BioPharma, Inc. (ABVC) - 424B5 SEC Filings 05/16/2022
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/16/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/12/2022
ABVC BioPharma, Inc. (ABVC) - DEF 14A SEC Filings 04/27/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/27/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/31/2022
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 03/31/2022
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 03/31/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/09/2022
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/22/2022
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 12/10/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 11/30/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 11/30/2021
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 11/24/2021
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 11/17/2021
ABVC BioPharma, Inc. (ABVC) - S-3/A SEC Filings 11/16/2021
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 11/15/2021
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/15/2021
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 11/05/2021
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 11/04/2021
ABVC BioPharma, Inc. (ABVC) - S-3 SEC Filings 10/29/2021
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 10/26/2021
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/08/2021
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 08/13/2021
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/12/2021
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/11/2021
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/05/2021
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 08/04/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 08/03/2021
ABVC BioPharma, Inc. (ABVC) - S-1MEF SEC Filings 08/03/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 08/02/2021
ABVC BioPharma, Inc. (ABVC) - CERT SEC Filings 08/02/2021
ABVC BioPharma, Inc. (ABVC) - 8-A12B SEC Filings 08/02/2021
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 07/29/2021
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 07/29/2021
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 07/28/2021
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 07/21/2021
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 06/21/2021
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 06/08/2021
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 05/14/2021
ABVC BioPharma, Inc. (ABVC) - 424B3 SEC Filings 05/14/2021
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 05/11/2021
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/10/2021
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 05/03/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 04/20/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 04/19/2021
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 04/15/2021
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 04/13/2021
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 04/08/2021
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 03/16/2021
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/11/2021
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/08/2021
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/07/2021
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 12/28/2020
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 12/28/2020
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 12/23/2020
ABVC BioPharma, Inc. (ABVC) - 424B4 SEC Filings 12/23/2020
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 12/22/2020
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 12/15/2020
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 12/15/2020
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 12/03/2020
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 11/24/2020
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 11/23/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/17/2020
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/17/2020
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 11/16/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/05/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/06/2020
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/14/2020
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 06/29/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/03/2020
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 05/15/2020
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 05/15/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/11/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/24/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/14/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/07/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/30/2020
ABVC BioPharma, Inc. (ABVC) - RW SEC Filings 02/24/2020
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/06/2019
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/18/2019
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 11/13/2019
ABVC BioPharma, Inc. (ABVC) - S-8 SEC Filings 11/12/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/01/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/15/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/11/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/17/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/05/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/27/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/13/2019
ABVC BioPharma, Inc. (ABVC) - 424B2 SEC Filings 08/09/2019
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/09/2019
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 08/08/2019
ABVC BioPharma, Inc. (ABVC) - EFFECT SEC Filings 08/07/2019
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 08/07/2019
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 08/06/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/06/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/01/2019
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 07/24/2019
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 07/24/2019
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 07/24/2019
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 07/16/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/12/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/03/2019
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 06/28/2019
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 06/28/2019
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/28/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/23/2019
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 05/15/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/08/2019
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 04/15/2019
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 04/02/2019
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 02/25/2019
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 02/14/2019
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 02/14/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/14/2019
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/01/2019
ABVC BioPharma, Inc. (ABVC) - S-4/A SEC Filings 01/16/2019
ABVC BioPharma, Inc. (ABVC) - S-4/A SEC Filings 12/26/2018
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 12/06/2018
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 11/14/2018
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 11/14/2018
ABVC BioPharma, Inc. (ABVC) - S-4/A SEC Filings 11/08/2018
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/20/2018
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/15/2018
ABVC BioPharma, Inc. (ABVC) - D SEC Filings 07/27/2018
ABVC BioPharma, Inc. (ABVC) - S-4 SEC Filings 07/23/2018
ABVC BioPharma, Inc. (ABVC) - RW SEC Filings 06/12/2018
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/15/2018
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/10/2018
ABVC BioPharma, Inc. (ABVC) - 10-KT - Current report SEC Filings 04/13/2018
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 04/03/2018
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 03/19/2018
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/12/2018
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/14/2018
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/05/2018
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 01/16/2018
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 12/29/2017
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/29/2017
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 11/28/2017
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/27/2017
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 10/06/2017
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 09/22/2017
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 09/22/2017
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 09/22/2017
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/20/2017
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/21/2017
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/14/2017
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 07/26/2017
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/24/2017
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 07/17/2017
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 07/17/2017
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 06/20/2017
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 06/15/2017
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/30/2017
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 05/24/2017
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 05/24/2017
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 05/22/2017
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/22/2017
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 05/22/2017
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 05/15/2017
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/22/2017
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 02/22/2017
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 02/22/2017
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 02/21/2017
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 02/15/2017
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 01/26/2017
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 01/19/2017
ABVC BioPharma, Inc. (ABVC) - AW SEC Filings 01/19/2017
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 01/12/2017
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 01/12/2017
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 01/12/2017
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 12/29/2016
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 12/02/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/30/2016
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 11/14/2016
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 11/14/2016
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 10/11/2016
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 09/13/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/30/2016
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/15/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/09/2016
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 05/17/2016
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/16/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/10/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/28/2016
ABVC BioPharma, Inc. (ABVC) - S-8 POS SEC Filings 03/15/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/01/2016
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 02/23/2016
ABVC BioPharma, Inc. (ABVC) - S-8 SEC Filings 02/17/2016
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 02/16/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/16/2016
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 01/29/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/08/2016
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/18/2015
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 11/27/2015
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 11/16/2015
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 09/08/2015
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/02/2015
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/19/2015
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/14/2015
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 06/05/2015
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/15/2015
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 04/17/2015
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 04/17/2015
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 04/16/2015
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 04/16/2015
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 04/15/2015
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 11/20/2014
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 11/19/2014
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 11/06/2014
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 11/05/2014
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/31/2014
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/24/2014
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/16/2013
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/03/2013
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/22/2013
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/19/2013
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 01/31/2013
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 01/23/2013
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 01/23/2013
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/18/2013
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 01/14/2013
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/10/2013
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 12/19/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/03/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/02/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/28/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/23/2012
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 08/20/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/16/2012
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/14/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/05/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/02/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/18/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/07/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/04/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/21/2012
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/15/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/01/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/17/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/29/2012
ABVC BioPharma, Inc. (ABVC) - SC 13G SEC Filings 03/01/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/28/2012
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 02/21/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/14/2012
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 02/09/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/06/2012
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 01/27/2012
ABVC BioPharma, Inc. (ABVC) - RW SEC Filings 01/18/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/18/2012
ABVC BioPharma, Inc. (ABVC) - RW SEC Filings 01/12/2012
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/03/2012
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 12/28/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/22/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/16/2011
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 12/16/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/15/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/29/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/01/2011
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 09/30/2011
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 09/22/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/14/2011
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 09/08/2011
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/15/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/15/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/11/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/06/2011
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 05/25/2011
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 05/19/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/19/2011
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/12/2011
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 05/11/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/14/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/28/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/14/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/15/2011
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 02/14/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/08/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/24/2011
ABVC BioPharma, Inc. (ABVC) - DEF 14A SEC Filings 01/20/2011
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 01/14/2011
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 01/13/2011
ABVC BioPharma, Inc. (ABVC) - PREM14A SEC Filings 01/11/2011
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/27/2010
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 12/20/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/08/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/02/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/18/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/22/2010
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 10/18/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/18/2010
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 10/07/2010
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 09/22/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/14/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/02/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/16/2010
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 08/13/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 07/07/2010
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 07/07/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/01/2010
ABVC BioPharma, Inc. (ABVC) - 5 SEC Filings 07/01/2010
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 07/01/2010
ABVC BioPharma, Inc. (ABVC) - 4/A SEC Filings 06/17/2010
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 06/07/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 05/24/2010
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 05/24/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/21/2010
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 05/20/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 05/20/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/18/2010
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 05/14/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/20/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/15/2010
ABVC BioPharma, Inc. (ABVC) - 5 SEC Filings 04/15/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/29/2010
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 02/17/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 02/17/2010
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 02/16/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/12/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 02/11/2010
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 02/11/2010
ABVC BioPharma, Inc. (ABVC) - 10-K/A - Current report SEC Filings 02/11/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/09/2010
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 01/19/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/19/2010
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 01/19/2010
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 01/12/2010
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/04/2010
ABVC BioPharma, Inc. (ABVC) - 10-K - Current report SEC Filings 12/22/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 12/18/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/18/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 12/18/2009
ABVC BioPharma, Inc. (ABVC) - AW SEC Filings 12/09/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/08/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/04/2009
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 11/23/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/20/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 11/16/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 11/16/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/13/2009
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 11/10/2009
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 10/20/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 10/08/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 10/05/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/02/2009
ABVC BioPharma, Inc. (ABVC) - 10-Q/A - Quarterly Report SEC Filings 09/25/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/23/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 09/23/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/21/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 09/16/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 09/16/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/11/2009
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 09/10/2009
ABVC BioPharma, Inc. (ABVC) - AW SEC Filings 09/10/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D/A SEC Filings 09/08/2009
ABVC BioPharma, Inc. (ABVC) - 4/A SEC Filings 09/08/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 09/03/2009
ABVC BioPharma, Inc. (ABVC) - S-1/A SEC Filings 09/03/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 09/02/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/01/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 08/24/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/24/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 08/21/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/20/2009
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 08/19/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/13/2009
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/11/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/11/2009
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 08/05/2009
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 07/31/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/31/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/29/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 07/28/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/27/2009
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 07/24/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/23/2009
ABVC BioPharma, Inc. (ABVC) - S-1 SEC Filings 06/23/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D/A SEC Filings 06/19/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 06/11/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 06/11/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/10/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 06/04/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 06/04/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/28/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 05/21/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/20/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D/A SEC Filings 05/08/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 05/05/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/05/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/30/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 04/30/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/28/2009
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 04/28/2009
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 04/16/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 04/15/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/15/2009
ABVC BioPharma, Inc. (ABVC) - 4/A SEC Filings 04/15/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 04/15/2009
ABVC BioPharma, Inc. (ABVC) - S-8 SEC Filings 04/09/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 03/30/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/27/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 03/27/2009
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 03/26/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/26/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 03/12/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 03/12/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/10/2009
ABVC BioPharma, Inc. (ABVC) - SC 13D SEC Filings 03/03/2009
ABVC BioPharma, Inc. (ABVC) - SC 13G SEC Filings 02/27/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/27/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 02/27/2009
ABVC BioPharma, Inc. (ABVC) - SC 13G SEC Filings 02/26/2009
ABVC BioPharma, Inc. (ABVC) - SC 13G SEC Filings 02/20/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/18/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 02/13/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/12/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 02/11/2009
ABVC BioPharma, Inc. (ABVC) - 10-Q - Quarterly Report SEC Filings 02/11/2009
ABVC BioPharma, Inc. (ABVC) - 4/A SEC Filings 02/09/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/30/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 01/26/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/23/2009
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/09/2009
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 12/29/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 12/24/2008
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 12/23/2008
ABVC BioPharma, Inc. (ABVC) - 10KSB SEC Filings 12/23/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/13/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/28/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/22/2008
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 10/02/2008
ABVC BioPharma, Inc. (ABVC) - 3/A SEC Filings 10/02/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/30/2008
ABVC BioPharma, Inc. (ABVC) - 4/A SEC Filings 09/22/2008
ABVC BioPharma, Inc. (ABVC) - 3/A SEC Filings 09/22/2008
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 09/22/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/19/2008
ABVC BioPharma, Inc. (ABVC) - 3/A SEC Filings 09/19/2008
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 09/18/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/17/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/08/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 09/03/2008
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 09/02/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/29/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/22/2008
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 08/20/2008
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 08/14/2008
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 08/14/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/12/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/30/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/18/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/17/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/24/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/11/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/22/2008
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 05/20/2008
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 05/15/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/16/2008
ABVC BioPharma, Inc. (ABVC) - 4 SEC Filings 04/09/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 04/03/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 03/20/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/22/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/14/2008
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 02/14/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 02/12/2008
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/03/2008
ABVC BioPharma, Inc. (ABVC) - 3/A SEC Filings 12/27/2007
ABVC BioPharma, Inc. (ABVC) - 10KSB SEC Filings 12/21/2007
ABVC BioPharma, Inc. (ABVC) - 3/A SEC Filings 12/11/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/23/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/16/2007
ABVC BioPharma, Inc. (ABVC) - CORRESP SEC Filings 09/17/2007
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 09/17/2007
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 09/07/2007
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 08/31/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/30/2007
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 08/20/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/15/2007
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/14/2007
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 08/09/2007
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 08/09/2007
ABVC BioPharma, Inc. (ABVC) - 3 SEC Filings 08/06/2007
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 08/01/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 07/30/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 06/13/2007
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 05/09/2007
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 04/20/2007
ABVC BioPharma, Inc. (ABVC) - 10KSB SEC Filings 03/02/2007
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 11/15/2006
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 11/15/2006
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 11/07/2006
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 08/14/2006
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 05/10/2006
ABVC BioPharma, Inc. (ABVC) - 10KSB SEC Filings 03/30/2006
ABVC BioPharma, Inc. (ABVC) - UPLOAD SEC Filings 01/06/2006
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 01/06/2006
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 01/06/2006
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 11/14/2005
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 08/31/2005
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 08/12/2005
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 05/20/2005
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 05/16/2005
ABVC BioPharma, Inc. (ABVC) - 10KSB SEC Filings 03/30/2005
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 11/15/2004
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 08/18/2004
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/16/2004
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 05/17/2004
ABVC BioPharma, Inc. (ABVC) - 10KSB/A SEC Filings 04/27/2004
ABVC BioPharma, Inc. (ABVC) - 10KSB SEC Filings 04/14/2004
ABVC BioPharma, Inc. (ABVC) - NT 10-K - Current report SEC Filings 03/30/2004
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 11/25/2003
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 11/14/2003
ABVC BioPharma, Inc. (ABVC) - 8-K/A - Current report SEC Filings 11/14/2003
ABVC BioPharma, Inc. (ABVC) - 8-K - Current report SEC Filings 10/17/2003
ABVC BioPharma, Inc. (ABVC) - POS AM SEC Filings 08/21/2003
ABVC BioPharma, Inc. (ABVC) - 10QSB SEC Filings 08/19/2003
ABVC BioPharma, Inc. (ABVC) - NT 10-Q - Quarterly Report SEC Filings 08/13/2003
ABVC BioPharma, Inc. (ABVC) - 424B1 SEC Filings 04/25/2003
ABVC BioPharma, Inc. (ABVC) - SB-2/A SEC Filings 03/27/2003
ABVC BioPharma, Inc. (ABVC) - SB-2/A SEC Filings 11/07/2002
ABVC BioPharma, Inc. (ABVC) - SB-2/A SEC Filings 09/20/2002
ABVC BioPharma, Inc. (ABVC) - SB-2 SEC Filings 06/28/2002

Press Releases

StockPrice Release
Abvc biopharma receives $50,000 in incremental licensing fees, boosting total payments to $346,000 from its three strategic partners 10/22/2024
Abvc biopharma, inc. reports strong q2 2024 financial results and strategic achievements 08/15/2024
Aibtl biopharma inc. acquired tt life company, valued at $8.33m, with 1.66m aibtl shares at $5 per share 04/18/2024
Abvc biopharma executes a global licensing definitive agreement for the treatment of nsclc, expecting aggregate income of $13.75m and royalties of up to $12.50m 04/17/2024
Abvc biopharma executes a global licensing term sheet for oncology/hematology products, expecting licensing income of $55m and royalties of up to $50m 04/10/2024
Abvc biopharma entered into a global licensing deal of vitargus with licensing income of $33.5m and royalties up to $60m 03/26/2024
Abvc biopharma, inc. ceo selected as 2024 top 10 ceo in ceo insights asia magazine 03/19/2024
Abvc biopharma reports annual 2023 financials and provides fiscal year 2024 first quarter business update 03/14/2024
Abvc biopharma executes a definitive agreement to receive license fees of $3m and royalties of 2% on future revenues 02/15/2024
Abvc biopharma receives australian patent, valid until 2040, for its treatment of major depressive disorder (mdd) 02/12/2024
Abvc acquires $2.96 million worth of land in asia with stocks priced at $3.50 per share 02/08/2024
Abvc biopharma and its subsidiary receive $460m from aibtl biopharma as the first milestone payment of global licensing fees 01/03/2024
Abvc biopharma announces completion of subject treatment for interim analysis on adhd phase iib clinical study 12/07/2023
Abvc biopharma receives u.s. patent for adhd treatment, a $32 billion market 11/21/2023
Abvc biopharma enters definitive agreement with licensing income worth $467m and royalties up to $200m 11/16/2023
Abvc biopharma reports third quarter 2023 financial and operational results 11/15/2023
Abvc biopharma entered into a term sheet to license global rights of cns drugs with the indications of mdd and adhd to aibtl biopharma at the valuation of $667 million 10/26/2023
Abvc biopharma announces completion of subject recruitment for interim analysis on adhd phase iib clinical study 10/17/2023
Abvc biopharma receives taiwanese patent for its treatment of major depressive disorder (mdd) 10/09/2023
Abvc biopharma provides updates on adhd phase iib clinical study 08/23/2023
Abvc executes cooperation agreement for strategic investments 08/17/2023
Abvc biopharma regains compliance with nasdaq's minimum bid price requirement 08/10/2023
Abvc corporate update and ceo's letter to shareholders 08/07/2023
Abvc announces the approval of the plan for gmp production facilities of vitargus by taiwan science park administration 08/03/2023
Abvc signs a term sheet to earn licensing fees of up to $20m and royalties of 5-12% of net sales 08/01/2023
Abvc biopharma announces closing on $1.75 million registered direct offering 07/31/2023
Abvc biopharma announces pricing of $1.75 million registered direct offering 07/27/2023
Abvc signs term sheet to acquire real estate assets for strategic investments 07/26/2023
Abvc biopharma announces reverse stock split 07/24/2023
The new ceo of abvc biopharma takes steps to help improve cash efficiency 07/06/2023
Abvc biopharma, inc. announces new ceo as it targets further growth 06/26/2023
Abvc biopharma subsidiary biokey projects $1.0 million proceeds from dietary supplement production 06/20/2023
Abvc biopharma adhd phase ii part 2 clinical study first subject enrolled at ucsf 06/12/2023
Abvc biopharma announces collaboration with merdury biopharma for new product development and commercialization 06/06/2023
Abvc biopharma vitargus® phase ii study received ethical approval at sydney eye hospital in australia 05/22/2023
Abvc biopharma provides abv-1601 update on phase i site initiation visit conducted at cedars-sinai medical center (csmc) 04/10/2023
Abvc biopharma provides vitargus update on phase ii site initiation visit conducted at ramathibodi hospital in thailand 04/06/2023
Abvc biopharma announces fiscal year 2022 financial and operational results 03/31/2023
Abvc biopharma provides vitargus® update on phase ii site initiation visit conducted at srinagarind hospital in thailand 03/20/2023
Abvc biopharma receives registration approval for maitake mushroom dietary supplement by the taiwan ministry of health and welfare 03/14/2023
Abvc biopharma provides 2023 pipeline update 02/28/2023
Abvc biopharma receives $3.175 million investment from the lind partners to continue clinical trials 02/23/2023
Abvc biopharma receives australian tga approval to initiate phase ii study of vitargus® 02/21/2023
Abvc biopharma abv-1505 adhd phase iia results presented at 2023 apsard conference 01/19/2023
Fda approves ind submission allowing abvc biopharma to proceed with clinical study of abv-1519 for treatment of non-small cell lung cancer 01/05/2023
Abvc biopharma provides vitargus® update - phase ii vitargus® study protocol received thai fda approval 11/17/2022
Abvc biopharma reports third quarter 2022 financial and operational results 11/14/2022
Global vitreo retinal surgery devices pipeline report 2022 update: formulate significant competitor information, analysis, and insights to improve r&d strategies - researchandmarkets.com 11/07/2022
Abvc biopharma receives notice of allowance from us patent and trademark office for abv-1504 used to treat major depressive disorder (mdd) 11/07/2022
Cedars-sinai medical center joins phase i clinical study of abvc biopharma's medication for treating depression in cancer patients 11/02/2022
Abvc biopharma announces vitargus® phase ii study plan approved by hrec in australia 10/05/2022
Abvc biopharma provides adhd phase ii part 2 clinical study update and announces ucsf institutional review board approval 09/23/2022
Abvc biopharma announces letter to shareholders 09/13/2022
Abvc biopharma selects additional vitargus® phase ii study site 09/09/2022
Abvc provides oncology pipeline updates 08/22/2022
Abvc biopharma provides vitargus® update 08/18/2022
Abvc biopharma reports second quarter 2022 financial and operational results 08/15/2022
Abvc biopharma provides vitargus® update 08/02/2022
Abvc notes new report that estimates global retinal surgical instruments market to grow to $2.46 billion by 2028 07/18/2022
Abvc biopharma provides adhd phase ii part 2 clinical update 07/13/2022
Zacks places share value of abvc biopharma at $9.50 07/06/2022
Abvc biopharma provides vitargus® update 06/30/2022
Abvc biopharma submitted vitargus® phase ii study plan to australia hrec 06/16/2022
Abvc biopharma announces termination of two contracts 06/10/2022
Abvc biopharma announces enrollment progress for adhd phase ii part 2 clinical study 06/01/2022
Abvc biopharma engaged by orion biotech to identify global licensing partners 05/25/2022
Prestigious researchers to provide consulting services in connection with abvc biopharma's depression medicines 05/23/2022
Abvc biopharma reports first quarter 2022 financial and operational results 05/16/2022
Wallachbeth capital announces completion of abvc biopharma, inc. (nasdaq: abvc) $4.22 million registered direct offering 05/16/2022
Abvc biopharma engages the freemind group to support grant funding 05/13/2022
Abvc biopharma adhd phase ii part 2 clinical study first subject treated 05/10/2022
Abvc biopharma enters into $3.0 million clinical services contract with neucen biomed 05/03/2022
Abvc biopharma completes site initiation visits and begins enrollments for adhd phase ii part 2 clinical study 04/28/2022
Abvc biopharma announces vitargus phase ii clinical study investigator meeting 04/26/2022
Abvc biopharma announces fiscal year 2021 financial and operational results 03/31/2022
Abvc biopharma to present at the maxim group 2022 virtual growth conference 03/23/2022
Abvc biopharma announces principal investigator meeting for phase ii part 2 adhd clinical study 02/02/2022
Abvc biopharma selects additional vitargus® phase ii study sites 01/05/2022
Abvc biopharma's vitreous substitute vitargus presented at 14th apvrs congress 12/22/2021
Abvc biopharma medical device vitargus receives taiwan national innovation award 12/15/2021
Abvc biopharma introduces dietary supplement based on maitake mushroom, enters into $3.0 million distribution agreement 12/09/2021
Abvc biopharma reports third quarter 2021 financial and operational results 11/15/2021
Central irb approved for abv-1505 phase ii part ii in taiwan sites 10/27/2021
Abvc biopharma announces new pct filings for mdd and adhd treatments 09/01/2021
Abvc biopharma report updated by zacks/scr 08/30/2021
Abvc biopharma provides vitargus® update 08/26/2021
Abvc biopharma reports second quarter 2021 results 08/12/2021
Abvc biopharma, inc. announces pricing of $6.875 million firm commitment offering 08/03/2021
Takeda und seattle genetics prÄsentieren positive daten aus klinischer phase-3-studie echelon-1 zur prÜfung von adcetris® (brentuximab vedotin) als erstlinientherapie bei fortgeschrittenem hodgkin-lymphom 12/11/2017

More Headlines

News
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024. 03/14/2024
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("Know-How") to Senior Paradise, Inc. ("SPI"), who will also lease certain of the Company's properties (the "Land") for further development related to the healthcare industry. The lease, SPI may build a long-term care center for the elderly, plant factories, and good agricultural practices (GAP) for botanical drug products and dietary supplements. 02/15/2024
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD). 02/12/2024
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries. 02/08/2024
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. ("AiBtl"), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party. 01/03/2024
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study FREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc . (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study. 12/07/2023
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD). 11/21/2023
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M. 11/16/2023
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company's Quarterly Report on Form 10-Q that was filed earlier today with the Securities and Exchange Commission 11/15/2023
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market. 10/26/2023
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. 10/26/2023
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study FREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc . (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment. 10/17/2023
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a Taiwanese patent, Application No. 109130285, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD). 10/09/2023
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study FREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company's ADHD Phase IIb clinical study. These subjects were enrolled at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. 08/23/2023
ABVC Executes Cooperation Agreement for Strategic Investments FREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it had entered into a Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology (Chengdu) Group Co., Ltd. (“中汇联和科技(成都)集团有限公司”) and its affiliated enterprises (“Zhonghui”). 08/17/2023
How to Find Cheap Penny Stocks to Make Money Trading Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/06/2023
5 Hot Penny Stocks Exploding After News This Week Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/05/2023
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating at the Maxim Group 2022 Virtual Growth Conference, taking place March 28-30, 2022. 03/23/2022
ABVC Biopharma Stock (ABVC): Why The Price Increased The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by 5.14% in the previous trading session. This is why it happened. 12/12/2021
Why ABVC BioPharma Shares Are Trading Higher On Friday? ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms. 12/10/2021
Hot Reddit Penny Stocks to Watch That Exploded Today Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/01/2021
ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today ABVC BioPharma (ABVC) stock is rocketing higher on Monday as investors on social media hype up the shares despite a lack of news. The post ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today appeared first on InvestorPlace. 11/01/2021
ABVC Biopharma stock is up 275% on Monday: explained here Shares of ABVC Biopharma Inc (NASDAQ: ABVC) are on fire this morning. The stock jumped nearly 300% on Monday as retail traders on StockTwits picked ABVC Biopharma as their next favourite. 11/01/2021
ABVC Stock: Why The Price Surged Today The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 300% pre-market today. This is why it happened. 11/01/2021
ABVC Stock: Why The Price Increased Today The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 25% pre-market today. This is why it happened. 10/15/2021
ABVC Stock: Why It Increased Today The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 2% during intraday trading today. This is why it happened. 10/12/2021
ABVC Stock: Over 40% Increase Pre-Market Explanation The stock price of ABVC BioPharma, Inc. (NASDAQ: ABVC) increased by over 40% pre-market. This is why it happened. 09/01/2021
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the company's MDD and ADHD drugs. 09/01/2021
ABVC BioPharma Report Updated by Zacks/SCR FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Zacks Small Cap Research has issued an update report on the company which may be accessed at: 08/30/2021
ABVC Stock: Over 28% Increase Explanation The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 28% during intraday trading. This is why it happened. 08/26/2021
ABVC BioPharma Provides Vitargus® Update FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update regarding recent developments in connection with Vitargus®, the world's first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. Early clinical studies indicate that Vitargus® has unique properties that result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater recovery period patient comfort and visual acuity than currently available products. 08/26/2021
ABVC BioPharma Reports Second Quarter 2021 Results Clinical Trials Continue Despite COVID-19 Restrictions 08/12/2021
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering FREMONT, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced the pricing of its firm commitment offering of 1,100,000 Units at an offering price of $6.25 per unit for total gross proceeds of $6.875 million. 08/03/2021
American BriVision: Deep Dive Into Market Potential American BriVision holds key differentiators via novel botanical treatment solutions in key end markets. 2 of the company's candidates have the potential to fulfil a wide treatment void. 01/14/2021

Unlock

ABVC Ratings Summary

ABVC Quant Ranking